![]() |
市場調查報告書
商品編碼
1576516
止血劑市場規模、佔有率、預測和趨勢分析:按類型、應用和最終用戶劃分 - 到 2031 年的全球預測Hemostats Market Size, Share, Forecast, & Trends Analysis by Type Form Application End User - Global Forecast to 2031 |
預計到 2031 年,止血劑市場將達到 53.2 億美元,2024 年至 2031 年的複合年增長率為 6.9%。
本報告在廣泛的二級和一級研究以及對市場情景的詳細分析後,對主要市場推動因素、阻礙因素、課題和機會進行了分析。該市場的成長是由癌症、心血管疾病、骨科疾病、神經系統疾病等慢性病患病率上升以及相關的手術量增加、事故率上升、剖腹產數量增加所推動的。活動的增加、醫療保健成本的上升以及對微創手術的日益偏好。然而,止血劑所用材料引起的過敏反應限制了該市場的成長。
此外,先進止血劑的使用不斷增加、牙科止血劑的進步以及對預裝施藥器和 RTU 止血劑的需求不斷增加,預計將為在該市場運營的公司提供增長機會。然而,止血劑的高製造成本和先進抗菌止血劑的高成本是影響市場成長的主要課題。
(註:提供上位5公司的SWOT分析)
Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User- Global Forecast to 2031
The hemostat market is projected to reach $5.32 billion by 2031 at a CAGR of 6.9% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. However, allergic reactions caused by the material used in making hemostats restrain the growth of this market.
Furthermore, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to generate growth opportunities for the players operating in this market. However, the high manufacturing cost for hemostasis and the high cost of advanced antimicrobial hemostatic agents are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the hemostat market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).
Among all the types studied in this report, in 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostat market. The segment's large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.
Among all the applications studied in this report, in 2024, the surgery segment is expected to account for the larger share of the hemostat market. The largest market share of this segment is attributed to the increasing number of surgeries, rise in the number of accidents, and growing demand for cosmetic/plastic surgeries. For instance, according to the World Health Organization (WHO), in 2021, yearly, 4.4 million people died from injuries, 3.16 million died from accidental wounds, and 1.25 million died from violence-related injuries globally.
Among all the forms studied in this report, in 2024, the matrix and gel segment is expected to account for the largest share of the hemostat market. The segment's large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.
Among all the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostat market. The growing number of surgeries conducted in hospitals, the use of hemostats for control of minor, moderate, and severe bleeding in operating rooms, the availability of different forms of hemostats used for surgical procedures, and the availability of favorable reimbursement policies are some of the major factors driving the growth of this segment.
An in-depth analysis of the geographical scenario of the hemostat market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 32.9% of the hemostat market. In the region in 2024, the U.S. is expected to account for the largest share of the hemostat market in North America. The large share of this regional market is attributed to the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.
Hemostat Market Assessment-by Type
Hemostat Market Assessment-by Application
Hemostat Market Assessment-by Form
Hemostat Market Assessment-by End User
Hemostat Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)